Skip to main content

Spondyloarthritis

9
Pipeline Programs
14
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
7100%
+ 10 programs with unclassified modality

On Market (1)

Approved therapies currently available

Eli Lilly and Company
TALTZApproved
ixekizumab
Eli Lilly and Company
Interleukin-17A Antagonist [EPC]injection2016

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
CLassification of Axial SpondyloarthritiS Inception CohortN/A
IxekizumabPHASE_3Monoclonal Antibody
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
AdalimumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT01174186Completed30Est. Mar 2014
MSD
MSDIreland - Ballydine
1 program
1
GolimumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT03253796Completed323Est. Mar 2021
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
GolimumabPhase 4Monoclonal Antibody
Prevail Therapeutics
4 programs
3
IxekizumabPhase 3Monoclonal Antibody1 trial
IxekizumabPhase 3Monoclonal Antibody1 trial
IxekizumabPhase 3Monoclonal Antibody1 trial
CLassification of Axial SpondyloarthritiS Inception CohortN/A1 trial
Active Trials
NCT03993847Completed501Est. Aug 2022
NCT02696798Completed316Est. May 2019
NCT02696785Completed341Est. Oct 2018
+1 more trials
Sandoz
SandozAustria - Kundl
2 programs
1
AIN457Phase 31 trial
CLassification of Axial SpondyloarthritiS Inception CohortN/A
Active Trials
NCT03136861Completed383Est. Feb 2019
Tasly Pharmaceutical
Tasly PharmaceuticalChina - Tianjin
1 program
1
Jitongning tabletPhase 21 trial
Active Trials
NCT03932019Completed238Est. Aug 2021
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
CLassification of Axial SpondyloarthritiS Inception CohortN/A
Pfizer
PfizerNEW YORK, NY
1 program
CLassification of Axial SpondyloarthritiS Inception CohortN/A
Amgen
AmgenTHOUSAND OAKS, CA
1 program
CLassification of Axial SpondyloarthritiS Inception CohortN/A
Novartis
NovartisBASEL, Switzerland
1 program
CLassification of Axial SpondyloarthritiS Inception CohortN/A
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
CLassification of Axial SpondyloarthritiS Inception CohortN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDGolimumab
MedtronicAdalimumab
Prevail TherapeuticsIxekizumab
SandozAIN457
Prevail TherapeuticsIxekizumab
Prevail TherapeuticsIxekizumab
Tasly PharmaceuticalJitongning tablet
Prevail TherapeuticsCLassification of Axial SpondyloarthritiS Inception Cohort

Clinical Trials (8)

Total enrollment: 2,279 patients across 8 trials

NCT03253796MSDGolimumab

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

Start: Nov 2017Est. completion: Mar 2021323 patients
Phase 4Completed
NCT01174186MedtronicAdalimumab

Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing

Start: Oct 2010Est. completion: Mar 201430 patients
Phase 4Completed
NCT04285229Prevail TherapeuticsIxekizumab

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Start: Apr 2020Est. completion: Mar 2022147 patients
Phase 3Completed
NCT03136861SandozAIN457

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Start: Jun 2017Est. completion: Feb 2019383 patients
Phase 3Completed
NCT02696785Prevail TherapeuticsIxekizumab

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Start: May 2016Est. completion: Oct 2018341 patients
Phase 3Completed
NCT02696798Prevail TherapeuticsIxekizumab

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

Start: Apr 2016Est. completion: May 2019316 patients
Phase 3Completed
NCT03932019Tasly PharmaceuticalJitongning tablet

Study of Jitongning Tablet to Treat Spondyloarthritis

Start: Jun 2019Est. completion: Aug 2021238 patients
Phase 2Completed
NCT03993847Prevail TherapeuticsCLassification of Axial SpondyloarthritiS Inception Cohort

CLassification of Axial SpondyloarthritiS Inception Cohort

Start: Dec 2019Est. completion: Aug 2022501 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.